AI-Powered News AnalysisCompare coverage across the political spectrum
Back to Dashboard
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO - Reuters

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO - Reuters

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO Reuters

June 11, 2026 at 07:29 PM Original source
6 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
0 articles
No coverage
Center
6 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Key People

No people linked to this story

Locations

No locations linked to this story

Tags

No tags linked to this story

All Coverage

Reutersvia rss

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOd3FqaXptWW5rQTg3MEVQNXJiVGM1aDJ6aGgtNHBqU29nM0Z1UkNJUnF2LXNMSmRqRkMtWEZ6RHNzeHJUMWtVSUMyMGVCZDBFN2UtRVp2c2V3Y2NGSWdxNzA2eDhyVk1lRDBWYzNaMVdscjdjLTRwQTJTNkdPUlZHVVdsNjBxVDIwR3ljSTNLc293REFsNUI3bm5aZWs0ajRPTGFlSm5hWkRWMlFPS3RxaU1WcUpSUUplRk4xV01wd0w2TEJDcXhMd0VYMWdwQkNGdTBB?oc=5" target="_blank">Heart drug developer Kardigan targets $1.4 billion valuation in US IPO</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

100%
Investing.comvia ai

Clinical-stage biotech Kardigan aims for a valuation of up to $1.4 billion in its U.S. IPO, seeking to raise up to $373.3 million by offering 23.3 million shares priced between $14 and $16 each.

80%
Investing.comvia ai

Kardigan has filed for a Nasdaq IPO, offering 23,333,334 shares at a price range of $14 to $16 per share.

80%
Investing.comvia ai

Kardigan aims for a valuation of up to $1.4 billion in its U.S. IPO, planning to raise up to $373.3 million by selling 23.3 million shares at a price range of $14 to $16 per share.

80%
Investing.comvia ai

Kardigan, Inc has filed for a proposed Nasdaq IPO under the ticker 'KARD', aiming to develop precision medicines for cardiovascular diseases.

80%
Investing.comvia ai

Kardigan filed for an initial public offering in the U.S. to fund the development of precision medicines for cardiovascular diseases.

80%